Limits...
Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus

The BCLC staging system for HCC. M, metastasis; N, node; PS, performance status; RFA, radiofrequency ablation.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562977&req=5

f0005: The BCLC staging system for HCC. M, metastasis; N, node; PS, performance status; RFA, radiofrequency ablation.

Mentions: The Barcelona Clinic Liver Cancer (BCLC) tumor staging classification combines the stage of the liver disease, tumor stage, clinical performance, and treatment options for HCC. For unresectable HCC intermediate stage (BCLC stage B or Child-Pugh class A/B with large or multifocal HCC, no vascular invasion, or extrahepatic spread), the current standard treatment is TACE as reported in Figure 1.


Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

The BCLC staging system for HCC. M, metastasis; N, node; PS, performance status; RFA, radiofrequency ablation.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562977&req=5

f0005: The BCLC staging system for HCC. M, metastasis; N, node; PS, performance status; RFA, radiofrequency ablation.
Mentions: The Barcelona Clinic Liver Cancer (BCLC) tumor staging classification combines the stage of the liver disease, tumor stage, clinical performance, and treatment options for HCC. For unresectable HCC intermediate stage (BCLC stage B or Child-Pugh class A/B with large or multifocal HCC, no vascular invasion, or extrahepatic spread), the current standard treatment is TACE as reported in Figure 1.

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus